Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
07:18am, Tuesday, 09'th Jul 2024
Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
10:39am, Monday, 01'st Jul 2024
Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used o
Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier'
04:31am, Monday, 01'st Jul 2024
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new
Hims & Hers shares fall on Hunterbrook report that GLP-1 drugs come from 'shady supplier'
06:13pm, Thursday, 27'th Jun 2024
Sam Koppelman, Hunterbrook Media publisher and co-founder, joins 'Closing Bell Overtime' to talk its report that Hims & Hers' GLP-1 offering is a 'knockoff' drug form 'shady supplier'.
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
03:35pm, Tuesday, 25'th Jun 2024
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initia
Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
08:30am, Tuesday, 25'th Jun 2024
New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Additional research demonstrates 31%
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
07:00am, Monday, 24'th Jun 2024
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism w
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions
01:30pm, Sunday, 23'rd Jun 2024
Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
04:55am, Friday, 21'st Jun 2024
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drug
GLP-1 drugs and other constraints in Kroger's pharmacies are crimping profits
01:31pm, Thursday, 20'th Jun 2024
Grocery-store chain Kroger Co. on Thursday reported better-than-expected first-quarter results, helped in part by more enthusiasm from wealthier shoppers, but executives warned that difficulties in th
Eli Lilly's Stock Surge Driven by GLP-1 Demand
07:04am, Thursday, 20'th Jun 2024
Most of the market focuses on the technology sector, with names like Nvidia Co. NASDAQ: NVDA receiving the lion's share. Among this hype and excitement, those companies worthy of investor capital have
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
09:00am, Tuesday, 18'th Jun 2024
Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a glo
Hims & Hers: The Undervalued Gem Poised For Growth
03:05am, Tuesday, 18'th Jun 2024
As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already star
Looking at Next Gen of Weight Loss: Tema ETFs CEO
02:46pm, Monday, 17'th Jun 2024
Tema Obesity & Cardiometabolic ETF (HRTS) currently holds 46 companies focused on GLP-1, obesity, and weight-loss. Tema ETFs CEO and Founder Maurits Pot says we're trying to build a product that goes
